# OnCo record paper-shalhout-oncolytic-progress-challenges-natrevclinonc-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-shalhout-oncolytic-progress-challenges-natrevclinonc-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-shalhout-oncolytic-progress-challenges-natrevclinonc-2023" ;
  schema:name "Shalhout 2023: what the approved oncolytic viruses actually do in practice"@en ;
  schema:description "A review of where cancer-killing viruses stand in the clinic, written around the accumulated experience of the one product that is widely approved."@en ;
  schema:url <https://onco.cc/key-papers/paper-shalhout-oncolytic-progress-challenges-natrevclinonc-2023/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1038/s41571-022-00719-w>, <https://pubmed.ncbi.nlm.nih.gov/36631681/> ;
  schema:sameAs <https://doi.org/10.1038/s41571-022-00719-w> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Shalhout SZ, Miller DM, Emerick KS, Kaufman HL" ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/oncolytic-virus/> ;
  onco:drugs <https://onco.cc/drugs/talimogene-laherparepvec/> ;
  onco:people <https://onco.cc/people/howard-kaufman/> ;
  onco:journals <https://onco.cc/journals/nature-reviews-clinical-oncology/> .